First Amendment Suit: FDA Draws Line At Amarin's Heart Disease Claim
This article was originally published in The Tan Sheet
Executive Summary
Amarin Pharmaceuticals’ marketing plan for its Rx fish oil drug Vascepa, including noting the qualified heart health claim allowed for omega-3 supplements, could “establish precedent that would return the country to ... when companies were not required to prove that their drugs were safe and effective for each of their intended uses,” FDA argues.
You may also be interested in...
Pharma-Related Probes Could Be Impacted By Departure Of US Attorneys
Ongoing cases led by New York's Preet Bharara and other US attorneys are unlikely to be affected though their successors could focus on different areas; Boston US Attorney Carmen Ortiz resigned in December.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.